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RESUMO
Introdução: A diabetes tipo 2 tem um peso significativo nas despesas com medicamentos. Determinámos a proporção de novos 
doentes que iniciaram tratamento com cada classe de antidiabéticos, se o tratamento foi iniciado pelos médicos de família, se estes 
alteram as prescrições de outros médicos e comparámos padrões de prescrição de médicos de família e outros especialistas.
Material e Métodos: Estudo transversal aninhado em coorte na Rede de Médicos Sentinela. Entre 2014 e 2015 casos incidentes de 
diabetes tipo 2 foram notificados, reportando o tratamento, quem fez a prescrição inicial e se tratamentos iniciados por outros médicos 
foram alterados.
Resultados: Foram notificados 415 casos incidentes. Os Médicos Sentinela fizeram a prescrição inicial em 89,4% dos casos (IC 95% 
86,0% - 92,0%). O tratamento inicial mais escolhido foi a metformina, em 85,5% dos doentes (IC 95% 81,8% - 88,6%). Os médicos 
de família utilizaram menos inibidores da dipeptidil peptidase-4 (4,2% vs 30,3%, p < 0,001) e insulina (0,3% vs 12,1%, p < 0,001) que 
outros especialistas. As prescrições iniciadas por outros foram alteradas em 4,5% dos casos (IC 95% 0,4% - 16,0%).
Discussão: A colheita prospectiva dos dados é um ponto forte, mas foram notificados poucos casos de tratamento iniciado por outros 
especialistas. Dados sobre a gravidade da doença não estavam disponíveis e podem explicar parte das diferenças entre médicos de 
família e outros especialistas.
Conclusão: A metformina foi o tratamento inicial mais escolhido, em linha com as recomendações das normas de orientação clínica 
Portuguesas. Os médicos da Rede Sentinela diagnosticaram a maioria dos casos, raramente alteraram prescrições iniciadas por 
outros e tiveram um padrão de prescrição diferente de outros especialistas.
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ABSTRACT
Introduction: Type 2 diabetes is a major driver of pharmaceutical spending. We aimed to determine the proportion of new patients 
who begin treatment with each antidiabetic medicine class, if therapy was initiated by their family physician, if family physicians alter 
prescriptions initiated by other physicians, and to compare prescribing patterns of family physicians and other specialists.
Material and Methods: Cohort-nested cross-sectional study within the Portuguese Sentinel Practice Network. Between 2014 and 
2015, incident cases of type 2 diabetes were notified, thus reporting treatment, who made the initial prescription and if treatments 
initiated by other physicians were changed.
Results: A total of 415 incident cases were notified. The initial prescription was made by Sentinel Practice Network physicians in 89.4% 
of cases (95% CI 86.0% - 92.0%). Metformin was most often chosen as the first treatment, prescribed to 85.5% of patients (95% CI 
81.8% – 88.6%). Family physicians used less dipeptidyl peptidase-4 inhibitors (4.2% vs 30.3%, p < 0.001) and insulin (0.3% vs 12.1%, 
p < 0.001) compared to other specialists. Prescriptions initiated by others were changed in 4.5% of cases (95% CI 0.4% - 16.0%).
Discussion: Prospective data collection is a major study strength, but few cases of treatment initiated by non-family physicians were 
notified. Data for disease severity was unavailable and could partly explain differences between family physicians and other specialists.
Conclusion: Metformin was most often chosen as initial therapy, in line with Portuguese guideline recommendations. Sentinel Practice 
Network physicians diagnosed most cases, seldom changed prescriptions initiated by others, and had a different pattern of antidiabetic 
medicines use compared to other specialists.
Keywords: Diabetes Mellitus, Type 2/drug therapy; Hypoglycemic Agents; Portugal; Primary Health Care; Sentinel Surveillance
INTRODUCTION
 Type 2 diabetes pharmacotherapy is one of the major 
drivers of pharmaceutical spending in Portugal and other 
developed countries.1 Rises in expense are partly related 
to increased diabetes prevalence, but mainly to the greater 
use of newer and more expensive medicines, such as the 
dipeptidyl peptidase-4 (DPP-4) inhibitors and insulin glar-
gine.1,2
 Both international and Portuguese guidelines favour 
metformin as the first-line agent of choice for most patients 
with type 2 diabetes after lifestyle changes have been 
tried.3,4 Portuguese guidelines prefer a sulfonylurea if met-
formin is contra-indicated or not tolerated, and recommend 
insulin if there is markedly symptomatic hyperglycaemia 
(with glycaemia above 300 mg/dL or an HbA1C over 10%).
4 
Starting with dual combination therapy is not recommended 
by Portuguese guidelines, but is considered optional for 
patients with HbA1C over 9% by the American Diabetes As-
sociation and the European Association for the Study of 
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Diabetes joint position statement.3
 Studies regarding diabetes medicines prescribing pat-
terns mainly focus on prevalent use,1,2,5,6 with only a few 
identifying the agents used as first-line therapy.7 Finding 
which agents are chosen as first-line therapy for new cases 
of type 2 diabetes may help determine if physicians are fol-
lowing guideline recommendations; and if more expensive 
agents are being used to initiate treatment or introduced 
later on (e.g., when initial therapy fails to achieve goals or 
causes side effects).
 Although family physicians account for most diabetes 
prescriptions in Portugal,1 it is unknown if new medicines 
are introduced by them or prescribing is induced by hospital 
or private practice based specialists. The influence of spe-
cialist prescribing of new medicines on primary care physi-
cians has been shown to occur often, but not in all cases. 
In some studies, specialists are earlier adopters, initiating 
treatments with a new drug, which family physicians then 
continue8-11; while in other studies family physicians are re-
ported to use new drugs more often.12
 The main objective of this study was to determine the 
proportion of new patients with type 2 diabetes who began 
treatment with each antidiabetic medicine class. Secondary 
objectives were to determine the proportion of new patients 
with type 2 diabetes whose initial therapy was prescribed by 
their family physician, the proportion of cases where family 
physicians altered prescriptions initiated by other doctors, 
and to compare family physicians prescribing patterns with 
private or hospital based specialists.
MATERIAL AND METHODS
Study design and setting
 The Portuguese Sentinel Practice Network is composed 
of volunteer family physicians working in the Portuguese 
National Health Service (NHS).13 The Portuguese NHS is 
a single payer publicly funded system, where each citizen 
is registered with a family physician.14 Therefore, each par-
ticipant in the Sentinel Practice Network contributes with a 
cohort of their patients. This allows the network to have a 
reasonably stable cohort each year and to calculate the in-
cidence of health problems in the Portuguese population. 
The network collects data for two different purposes: sur-
veillance of communicable and non-communicable diseas-
es for which specified events are systematically reported 
each week; and epidemiological research that comprises 
satellite studies, where data is collected to answer a spe-
cific question. Only observational research studies are per-
formed within the network.
 In 2013, the network agreed to expand the information 
being collected about incidence of diabetes mellitus for 
surveillance purposes, to conduct a continuous notification 
cross-sectional study among new cases of type 2 diabetes 
notified in the cohort. Data was collected from January 2014 
to December 2015.
Participants
 In 2014 and 2015 there were 82 active family physicians 
participating in the Portuguese Sentinel Practice Network, 
which comprised an observed population of 35 535 indi-
viduals. We asked participants to notify all incident cases of 
diabetes of any age. Diagnosis of diabetes was made using 
the nationally adopted criteria (the same as those recom-
mended by the World Health Organization in 2006, updated 
in 2011 to include HbA1C).
15 Only cases of type 2 diabetes 
were included.
Measurements
 Notifications were sent using either online or paper 
forms. Data were collected on patient age at diagnosis, 
gender, type of diabetes (type 1, type 2 – only these were 
included, gestational, other or unknown), pharmacological 
treatment (the online form had a list of marketed antidiabet-
ic medicines using the international non-proprietary name; 
the paper form had a free text space; up to three medicines 
could be entered), other treatment measures (free text), 
who made the initial prescription (the family physician or 
another doctor, who was then specified in a separate free 
text field), and if the initial prescription had been changed by 
the family physician (only for prescriptions initiated by other 
physicians). Free text fields were later coded by the inves-
tigators. When incomplete submissions were received, the 
Sentinel Practice Network coordination contacted the noti-
fying physician to gather missing information.
Outcomes
 Our main outcome was the proportion of patients who 
began treatment with each antidiabetic medicine class. 
Classes were defined using the Anatomical Therapeutic 
Chemical classification categories for A10B blood glucose 
lowering drugs excluding insulins and A10A insulins and 
analogues.16
 Secondary outcomes were the proportion of patients 
whose diagnosis and initial therapy was prescribed by their 
family physician; the proportion of cases where family phy-
sicians altered prescriptions initiated by others; and the pro-
portion of each class of antidiabetics prescribed by primary 
care physicians (family physicians participating in the Sen-
tinel Practice Network or other family medicine specialists) 
or private and hospital based specialists.
Study size
 We calculated a minimum sample size of 384 cases of 
type 2 diabetes needed to estimate the proportion of pa-
tients beginning treatment with each class of antidiabetic 
medicines with 5% precision and a 95% confidence inter-
val, assuming as worst-case scenario that 50% of patients 
would begin with one class. Given the previous notification 
rate, we estimated that two or three years of continuous 
notification would be needed. To maximize the ability of the 
network to conduct new projects, we planned to count the 
number of notifications by the last trimester of the second 
year and only continue notifications into the third year if the 
desired sample size had not been achieved.
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Statistical analysis
 Proportions of each antidiabetic class prescribed as 
initial therapy were estimated with their respective 95% 
confidence interval (95% CI). Proportions of medicines pre-
scribed by primary care and non-primary care physicians 
were compared using Fisher’s exact test. A level of signifi-
cance (α) of 0.01 was used as the threshold for statistical 
significance to account for multiple comparisons.
Ethics approval
 This study was approved by the Ethics Committee of 
National Health Institute Dr. Ricardo Jorge (Portugal).
RESULTS
 During the years 2014 and 2015, 415 incident cases of 
type 2 diabetes were notified to the Portuguese Sentinel 
Practice Network by 72 participating family physicians. Ten 
physicians did not contribute with any diabetes notifications, 
but, as they notified other health conditions under obser-
vation, their patient lists were included when calculating 
incidence. Having achieved the planed sample size, data 
collection ended by the end of the second year of the study. 
Type 2 diabetes incidence in the cohort was 5.8 / 1000 per-
son-years. Median age at diagnosis was 62 (interquartile 
range 54 - 71) and 54.5% of patients were male. There were 
no differences between patients diagnosed by primary care 
and non-primary care physicians regarding mean age (62.7 
vs 60.2 years, p = 0.25) and gender (53.7 vs 63.6% male, 
p = 0.28).
 The diagnosis and initial prescription were made by phy-
sicians participating in the Sentinel Practice Network in 371 
cases (89.4%, 95% CI 86.0% - 92.0%), other family physi-
cians in 11 cases (2.7%, 95% CI 1.4% - 4.7%), and other 
specialists in 33 cases (8.0%, 95% CI 5.7% - 11.0%).
 Lifestyle changes alone were introduced in 12.0% (95% 
CI 9.2% - 15.6%) of patients, and all were prescribed by 
Sentinel Practice network physicians. In total, lifestyle 
changes were prescribed in 65.8% (95% CI 61.1% - 70.2%) 
of cases.
 In 81.4% (95% CI 77.4% - 84.9%) of cases patients 
were started on one single medicine, in 5.8% (95% CI 
3.9% - 8.5%) two medicines were used and in 0.7% (95% 
CI 0.1% - 2.2%) three antidiabetic drugs were prescribed. 
Family physicians used two or more medicines less often 
than other specialists (4.2% vs 33.3%, p < 0.001). Fixed 
associations were used in 3.4% of cases, less often by pri-
mary care physicians compared to other specialists (2.4% 
vs 15.2%, p = 0.003).
 Tables 1 and 2 show the proportion of each antidiabetic 
class prescribed as initial therapy by family physicians or 
Table 1 – Proportion of patients prescribed each distinct combination for initial therapy (by class and type of practitioner). Antidiabetics with 
and without associated prescription for lifestyle changes are grouped together.
Initial therapy Family physicians(n = 382)
Other specialists
(n = 33)
Total 
(n = 415)
% (95%CI)
Lifestyle changes alone 13.1 (10.1 – 16.9) 0.0 (0.0 – 12.4) 12.0 (9.2 – 15.6)
Biguanides (metformin) 81.4 (77.2 – 85.0) 54.5 (38.0 – 70.2) 79.3 (75.1 – 82.9)
Biguanide and DPP-4-i 2.4 (1.2 – 4.5) 24.2 (12.6 – 41.2) 4.1 (2.5 – 6.5)
DPP-4-i 1.0 (0.3 – 2.8) 6.1 (0.6 – 20.6) 1.4 (0.6 – 3.2)
Biguanide and sulphonylurea 1.0 (0.3 – 2.8) 0.0 (0.0 – 12.4) 1.0 (0.3 – 2.5)
Insulin 0.0 (0.0 – 1.2) 9.1 (2.4 – 24.3) 0.7 (0.1 – 2.2)
Biguanide, sulphonylurea and DPP-4-i 0.5 (0.0 – 2.0) 0.0 (0.0 – 12.4) 0.5 (0.0 – 1.9)
Sulphonylureas 0.3 (0.0 – 1.6) 0.0 (0.0 – 12.4) 0.2 (0.0 – 1.5)
Biguanide and GLP1 agonist 0.0 (0.0 – 1.2) 3.0 (0.0 – 16.7) 0.2 (0.0 – 1.5)
Biguanide and insulin 0.0 (0.0 – 1.2) 3.0 (0.0 – 16.7) 0.2 (0.0 – 1.5)
Biguanide, DPP-4-i and insulin 0.3 (0.0 – 1.6) 0.0 (0.0 – 12.4) 0.2 (0.0 – 1.5)
DPP-4-i: dipeptidyl peptidase-4 inhibitor; GLP1: glucagon-like peptide-1: 95% CI: 95% confidence interval
Table 2 – Proportion of patients prescribed each class as part of their initial therapy (alone or in combinations)
Initial therapy Family physicians(n = 382)
Other specialists
(n = 33)
Total 
(n = 415)
% (95%CI)
Lifestyle changes 68.3 (63.5 – 72.8) 36.4 (22.1 – 53.4) 65.8 (61.1 – 70.2)
Biguanides (metformin) 85.6 (81.7 – 88.8) 84.8 (68.6 – 93.8) 85.5 (81.8 – 88.6)
DPP-4-i 4.2 (2.5 – 6.7) 30.3 (17.3 – 47.5) 6.3 (4.3 – 9.1)
Sulphonylureas 1.8 (0.8 – 3.8) 0.0 (0.0 – 12.4) 1.7 (0.8 – 3.5)
Insulin 0.3 (0.0 – 1.6) 12.1 (4.2 – 27.9) 1.2 (0.4 – 2.9)
GLP-1 agonists 0.0 (0.0 – 1.2) 3.0 (0.0 – 16.7) 0.2 (0.0 – 1.5)
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other specialists grouped by distinct combinations and to-
tal class use, respectively. Metformin was used as a sin-
gle agent or in combinations in 85.5% of patients (95% 
CI 81.8% – 88.6%), with no differences between primary 
care and non-primary care physicians (85.6% vs 84.8%, 
p = 0.801). Metformin alone was used more often by fam-
ily physicians than other specialists (81.4% vs 54.5%, p = 
0.01). Sulphonylureas alone or in combination were used in 
1.7% of cases (95% CI 0.8% - 3.5%), with no differences be-
tween primary care physicians and other specialists (1.8% 
vs 0.0%, p = 1.0). The proportion of patients who began 
treatment with a DPP-4 inhibitor as a single agent or in com-
bination was 6.3% (95% CI 4.3% - 9.1%), 4.2% for primary 
care physicians and 30.3% for other specialists (p < 0.001). 
Insulin alone or in combination was prescribed to 1.2% (95% 
CI 0.4% - 2.9%) of cases, by family physicians to 0.3% of 
patients and by other specialists to 12.1% (p < 0.001). 
 When we excluded cases treated with lifestyle changes 
alone, the differences between family physicians and other 
specialists in use of metformin alone (93.7% for family phy-
sicians vs 54.5% for specialists, p < 0.001), DPP-4 inhibi-
tors (4.8% vs 30.3%, p < 0.001) and insulin (0.3% vs 12.1%, 
p < 0.001) as single agents or in combinations, and fixed 
combination therapy (2.7% vs 15.2%, p = 0.005) remained 
statistically significant. Total metformin use (as a single 
agent or in combinations) also achieved statistical signifi-
cance (98.5% vs 84.5%, p = 0.001). There were still no dif-
ferences in sulphonylurea use (2.1% vs 0%, p = 1.0).
 Among the 44 cases where treatment was not initiated 
by physicians participating in the Sentinel Practice Net-
work, the prescribed medicines were changed in two cases 
(4.5%, 95% CI 0.4% - 16.0%).
DISCUSSION
Main findings
 In this study, most cases of type 2 diabetes were di-
agnosed by family physicians. The majority of patients be-
gan treatment with metformin as a single agent, as recom-
mended by Portuguese and international guidelines.3,4 This 
occurred more often when treatment was initiated by family 
physicians than when initiated by other specialists. Lifestyle 
changes alone were the initial strategy used by family phy-
sicians in about 13% of patients, but in none of the cases 
diagnosed by other specialists. When these two options 
are taken together, family physicians managed new cases 
of type 2 diabetes with lifestyle changes or metformin in 
94.5% of cases, compared with 54.5% of cases diagnosed 
by specialists. Other specialists were more likely than family 
physicians to use DPP-4 inhibitors, insulin or fixed combina-
tions as their initial choice. Despite these differences, family 
physicians usually didn’t change prescriptions initiated by 
others.
 Sulphonylureas and glucagon-like peptide-1 receptor 
agonists were seldom used as first-line agents. We ob-
served no use of alpha glucosidase inhibitors, thiazolidin-
ediones or sodium/glucose cotransporter 2 inhibitors as 
initial therapy.
Strengths and limitations
 The main strength of this study is the prospective data 
collection about therapeutic choices among new cases of 
diabetes. Almost 90% of cases were reported by the pre-
scribers themselves on the same day or a few days after 
the diagnosis and a therapeutic decision had been made. 
For the remaining 10% of cases, Sentinel Practice Network 
physicians gathered information from the patient or avail-
able patient records. In the Portuguese NHS, electronic 
prescription has been mandatory for reimbursement since 
August 2011.17 Information about electronic prescriptions 
made elsewhere is available to family physicians through 
the national Health Data Platform.18 The availability of such 
information would have limited patient recall bias.
 There may have been some cases of type 2 diabetes 
diagnosed by other physicians that were not reported by 
participants in the Sentinel Practice Network. However, 
these should be rare, as the diagnosis of type 2 diabetes 
grants special benefits to patients in the Portuguese NHS 
and most would visit their family physician to be entitled to 
them. Also, incidence during the study period was similar 
to that previously reported in the cohort (since here we are 
only considering type 2 diabetes),19 and to what is reported 
in other countries (considering these are estimates for the 
adult population only).20-22
 It is possible that patients diagnosed by other special-
ists who were prescribed lifestyle changes alone would not 
come immediately to their family physician, reporting their 
diagnosis only when medicines are prescribed. However, 
when we excluded patients treated with lifestyle changes 
alone the differences in prescribing pattern did not disap-
pear. Sentinel Practice Network participants could also 
have underreported lifestyle changes prescribed by other 
physicians, as patients may have not valued non-pharma-
cological treatment and there were no other sources of this 
information.
 We did not collect data on disease severity or presence 
of contra-indications to specific medicines. Both could influ-
ence the decision of initial treatment. However, the number 
of variables that can be collected in the Sentinel Practice 
Network is limited, as the paper notification form for all stud-
ies in a given year has to fit in one sheet.
 Socio-economic status may have been a confounder, as 
patients with more purchasing power may have been more 
likely not to use the NHS and also to afford more expensive 
medicines.
 An important limitation is that family physicians partici-
pating in the Sentinel Practice Networks might sometimes 
have different prescribing habits than other family physi-
cians. Participating in a research network is voluntary and 
could be associated with other physician or patient charac-
teristics that influence prescribing. This has not been thor-
oughly studied in the Portuguese Sentinel Practice Network, 
but other authors have found differences to be small.23,24
 Care must be taken when interpreting differences in use 
of specific drugs, as we did multiple comparisons, which 
make false positive results more likely, and this was not the 
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study’s primary outcome. Therefore, our findings should be 
considered mostly as hypothesis generating. Nonetheless, 
we decided to use a lower than usual threshold for statisti-
cal significance (α = 0.01 instead of α = 0.05) to reduce false 
discovery rate. A formal adjustment method, such as the 
Bonferroni correction, was not defined in the study’s meth-
ods since the number of comparisons to make would be 
dependent on the number of medicines classes used in our 
sample. Even so, most of the associations found were very 
unlikely to be due to chance, with a p value less than 0.001.
Interpretation of results
 As expected, metformin was the most frequently pre-
scribed first-line medicine, followed by DPP-4 inhibitors, 
mainly when used in a fixed association with metformin, with 
sulphonylureas coming in third place. This goes against rec-
ommendations in Portuguese guidelines, which favour sul-
phonylureas for having a better cost-benefit relationship.4 It 
may, however, reflect physician perception of better safety 
with DPP-4 inhibitors,25 despite their sparse data on reduc-
tion of diabetes complications.26
 Our findings suggest family physicians prescribe more 
in line with guidelines than other specialists, who use more 
intensive pharmaceutical regimens, including newer and 
more expensive medicines. This may be partially explained 
by other specialists seeing patients with more severe dis-
ease, possibly with symptomatic hyperglycaemia – data 
which we were unable to collect. Since the study did not col-
lect information on disease severity at diagnosis, we are un-
able to test this hypothesis. Alternatively, specialists might 
be more willing to use newer medicines or feel more often 
that their patients do not fit guideline recommendations.10,27 
However, our results are consistent with a study conducted 
in the Lisbon region that showed only 17.2% of initial pre-
scriptions for new oral anticoagulant agents originated in 
primary care.11
 Family physicians seem to be reluctant to change pre-
scriptions initiated by other specialists. This might be ex-
plained by the fact that most these patients would continue 
to be followed by those specialists. On the other hand, fam-
ily physicians might feel compelled to keep the treatment 
initiated by other specialists, feel they do not have all the 
information needed to recommend a different treatment or 
patients might be resistant to change.28
Implications for practice
 When considering prevalent prescribing patterns of 
antidiabetic medicines, policy and decision makers should 
consider that most patients diagnosed with type 2 diabetes 
start with metformin, and probably only escalate to other 
treatments later in the natural history of the disease. How-
ever, more aggressive initial treatment, including more ex-
pensive agents, is more frequent when the diagnosis has 
not been made by family physicians. Thus, interventions to 
alter prescription patterns need to target hospital and pri-
vate-based specialists and not only primary care doctors.
 Future studies should address disease severity at diag-
nosis, but also when and why patients change their initially 
prescribed treatment as the duration of diagnosis lengthens 
and which agents are chosen by physicians then.
CONCLUSION
 Metformin was the agent most often chosen as initial 
therapy, followed by lifestyle changes alone, fixed combi-
nations of metformin and DPP-4 inhibitors and DPP-4 in-
hibitors. The diagnosis and initial prescription were made 
by Sentinel Practice Network physicians in almost 90% of 
cases. Family physicians changed prescriptions initiated by 
others in less than 5% of cases. DPP-4 inhibitors and insu-
lin were more likely to be prescribed by other specialists.
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